The PD-L1xCD3 BiTE platform targets the PD-L1 protein on the target tumor at one site, which consequently blocks PD-1/PD-L1 signaling, and it also binds to CD3 on T cells, which results in T cell activation and the killing of cancer cells14,15. This evidence concerns the gene PDCD1 and neoplasm.